Vaccines growth offsets Advair generic pain for GSK

Growth in GlaxoSmithKline’s (GSK) vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair (fluticasone propionate/salmeterol) on its sales.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Ionis licenses chronic hepatitis B treatments to GSK

28 August 2019 Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline.

Americas

GSK sues Chinese company over Advair Diskus TMs

26 March 2019 Pharmaceutical company GSK has taken a Chinese company to court over its alleged “deliberate and unlawful campaign” to copy GSK’s trademarks.

Americas

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.